Literature DB >> 25178777

Establishment of a novel diagnostic model for Sjögren's syndrome by proteomic fingerprinting.

Yuhui Li1, Xiaolin Sun, Xuewu Zhang, Yuqin Yang, Rulin Jia, Xu Liu, Ru Li, Yanying Liu, Zhanguo Li.   

Abstract

Primary Sjögren's syndrome (pSS) is a systemic autoimmune disease that lacks sensitive and specific diagnostic methods. The aim of this study was to identify potential biomarkers specific for pSS and to establish a diagnostic model. Serum samples from patients with pSS, disease controls (DC, patients with systemic lupus erythematosus (SLE), rheumatoid arthritis (RA)), and healthy controls (HC)) were randomly divided into a training set (35 pSS, 50 DC, and 26 HC) and a testing set (25 pSS, 50 DC, and 25 HC). Weak cationic exchange (WCX) magnetic beads were used to differentially capture serum proteins prior to proteomic analysis. Proteomic mass spectra were generated by matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF-MS). One hundred differential M/Z peaks associated with pSS were identified, and the m/z peaks at 8,133.85, 11,972.8, 2,220.81, and 4,837.66 were used to establish a diagnostic model for pSS. This diagnostic model was able to distinguish pSS from non-pSS controls with a sensitivity of 77.1 % and a specificity of 85.5 %, and its efficacy was confirmed in our blinded testing set with good sensitivity and specificity of 95.5 and 88 %, respectively. The results indicated that the proteomic fingerprinting model was effective in the diagnosis of pSS.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25178777     DOI: 10.1007/s10067-014-2762-4

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  24 in total

Review 1.  Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group.

Authors:  C Vitali; S Bombardieri; R Jonsson; H M Moutsopoulos; E L Alexander; S E Carsons; T E Daniels; P C Fox; R I Fox; S S Kassan; S R Pillemer; N Talal; M H Weisman
Journal:  Ann Rheum Dis       Date:  2002-06       Impact factor: 19.103

2.  2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.

Authors:  Daniel Aletaha; Tuhina Neogi; Alan J Silman; Julia Funovits; David T Felson; Clifton O Bingham; Neal S Birnbaum; Gerd R Burmester; Vivian P Bykerk; Marc D Cohen; Bernard Combe; Karen H Costenbader; Maxime Dougados; Paul Emery; Gianfranco Ferraccioli; Johanna M W Hazes; Kathryn Hobbs; Tom W J Huizinga; Arthur Kavanaugh; Jonathan Kay; Tore K Kvien; Timothy Laing; Philip Mease; Henri A Ménard; Larry W Moreland; Raymond L Naden; Theodore Pincus; Josef S Smolen; Ewa Stanislawska-Biernat; Deborah Symmons; Paul P Tak; Katherine S Upchurch; Jirí Vencovsky; Frederick Wolfe; Gillian Hawker
Journal:  Ann Rheum Dis       Date:  2010-09       Impact factor: 19.103

3.  Differential capture of serum proteins for expression profiling and biomarker discovery in pre- and posttreatment head and neck cancer samples.

Authors:  Gary L Freed; Lisa H Cazares; Craig E Fichandler; Thomas W Fuller; Christopher A Sawyer; Brendan C Stack; Scott Schraff; O John Semmes; J Trad Wadsworth; Richard R Drake
Journal:  Laryngoscope       Date:  2008-01       Impact factor: 3.325

4.  American College of Rheumatology classification criteria for Sjögren's syndrome: a data-driven, expert consensus approach in the Sjögren's International Collaborative Clinical Alliance cohort.

Authors:  S C Shiboski; C H Shiboski; L A Criswell; A N Baer; S Challacombe; H Lanfranchi; M Schiødt; H Umehara; F Vivino; Y Zhao; Y Dong; D Greenspan; A M Heidenreich; P Helin; B Kirkham; K Kitagawa; G Larkin; M Li; T Lietman; J Lindegaard; N McNamara; K Sack; P Shirlaw; S Sugai; C Vollenweider; J Whitcher; A Wu; S Zhang; W Zhang; J S Greenspan; T E Daniels
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-04       Impact factor: 4.794

5.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.

Authors:  M C Hochberg
Journal:  Arthritis Rheum       Date:  1997-09

6.  Use of proteomic patterns in serum to identify ovarian cancer.

Authors:  Emanuel F Petricoin; Ali M Ardekani; Ben A Hitt; Peter J Levine; Vincent A Fusaro; Seth M Steinberg; Gordon B Mills; Charles Simone; David A Fishman; Elise C Kohn; Lance A Liotta
Journal:  Lancet       Date:  2002-02-16       Impact factor: 79.321

7.  Detection of colorectal cancer using MALDI-TOF serum protein profiling.

Authors:  Mirre E de Noo; Bart J A Mertens; Aliye Ozalp; Marco R Bladergroen; Martijn P J van der Werff; Cornelis J H van de Velde; Andre M Deelder; Rob A E M Tollenaar
Journal:  Eur J Cancer       Date:  2006-04-17       Impact factor: 9.162

8.  Oral cancer plasma tumor marker identified with bead-based affinity-fractionated proteomic technology.

Authors:  Ann-Joy Cheng; Li-Chiu Chen; Kun-Yi Chien; Yin-Ju Chen; Joseph Tung-Chieh Chang; Hung-Ming Wang; Chun-Ta Liao; I-How Chen
Journal:  Clin Chem       Date:  2005-10-20       Impact factor: 8.327

9.  Mortality and causes of death in primary Sjögren's syndrome: a prospective cohort study.

Authors:  Elke Theander; Rolf Manthorpe; Lennart T H Jacobsson
Journal:  Arthritis Rheum       Date:  2004-04

10.  Enrichment and detection of molecules secreted by tumor cells using magnetic reversed-phase particles and LC-MALDI-TOF-MS.

Authors:  Jochen F Peter; Angela M Otto; Bernhard Wolf
Journal:  J Biomol Tech       Date:  2007-12
View more
  2 in total

1.  Establishing Classification Tree Models in Rheumatoid Arthritis Using Combination of Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry and Magnetic Beads.

Authors:  Dan Ma; Nana Liang; Liyun Zhang
Journal:  Front Med (Lausanne)       Date:  2021-02-24

Review 2.  Application of machine learning in the diagnosis of axial spondyloarthritis.

Authors:  Jessica A Walsh; Martin Rozycki; Esther Yi; Yujin Park
Journal:  Curr Opin Rheumatol       Date:  2019-07       Impact factor: 5.006

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.